APA

Malottki K., Barton P., Tsourapas A., Uthman A. O., Liu Z., Routh K., Connock M., Jobanputra P., Moore D., Fry-Smith A. & Chen Y. (20110805). Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. : Health technology assessment (Winchester, England).

Chicago

Malottki K, Barton P, Tsourapas A, Uthman A O, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A and Chen Y-F. 20110805. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. : Health technology assessment (Winchester, England).

Harvard

Malottki K., Barton P., Tsourapas A., Uthman A. O., Liu Z., Routh K., Connock M., Jobanputra P., Moore D., Fry-Smith A. and Chen Y. (20110805). Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. : Health technology assessment (Winchester, England).

MLA

Malottki K, Barton P, Tsourapas A, Uthman A O, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A and Chen Y-F. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. : Health technology assessment (Winchester, England). 20110805.